San Francisco, United States
Airja, Inc. is a pioneering medical device company specializing in the development and licensing of patent-protected respiratory drug delivery products. With a team boasting over 50 years of combined pharmaceutical and entrepreneurial successes, Airja has introduced patented technology that revolutionizes respiratory drug delivery. The company's mission is centered on instilling confidence, safety, accuracy, and convenience in drug delivery. Their innovative solutions span across the pharmaceutical technology and cannabinoid vape spheres, encompassing precise aerosol particle size control, immediate treatment for various indications, and breakthroughs in cannabinoid vape technology. Airja, Inc. was founded in 2019, targeting opportunities in the pharmaceutical industry.
Given their pioneering approach to drug delivery, Airja, Inc. poses an exciting investment opportunity for venture capital firms seeking to tap into the potential of groundbreaking medical technology. As the company operates in stealth mode, it offers an intriguing prospect for licensing opportunities, investment, or joint development initiatives. For further details or to explore collaboration, interested parties can contact Beverly Connelly via email at [email protected].
